Literature DB >> 8467562

Cytokines involved in the progression of multiple myeloma.

F Merico1, L Bergui, M G Gregoretti, P Ghia, G Aimo, I J Lindley, F Caligaris-Cappio.   

Abstract

We have investigated which of the cytokines that are relevant in the in vitro growth of multiple myeloma (MM) malignant plasma cells are actually produced in vivo by MM patients. To this end, we have measured the levels of IL-1 beta, IL-3, IL-4, IL-6, IL-7, IL-8 and tumour necrosis factor-alpha (TNF-alpha) both in sera and in the supernatant of bone marrow (BM) stromal cell cultures from patients with MM and monoclonal gammopathy of undetermined significance (MGUS). The significance of our findings is three-fold. First, IL-6 and IL-8 are produced by MM BM stromal cells, while IL-1 beta, TNF-alpha, IL-4 and IL-7 are not. Second, IL-3 is the only cytokine consistently raised in serum samples: we have also detected low levels of serum IL-6 in a minority of cases, usually in advanced stage of the disease. Third, MM BM stromal cells are active IL-6 and IL-8 producers, while both normal and MGUS BM stromal cells are low producers, thus suggesting that in the BM of MM a number of environmental cells, that would normally be quiescent, are instead activated and that, in MM, activated BM stromal cells play an active role in supporting the progressive expansion of the B cell clone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467562      PMCID: PMC1554871          DOI: 10.1111/j.1365-2249.1993.tb05943.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Interleukin-6 is a prognostic factor in multiple myeloma.

Authors:  H Ludwig; D M Nachbaur; E Fritz; M Krainer; H Huber
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

2.  Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.

Authors:  X G Zhang; R Bataille; M Jourdan; S Saeland; J Banchereau; P Mannoni; B Klein
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

Review 3.  Cytokine network in human multiple myeloma.

Authors:  B Klein; R Bataille
Journal:  Hematol Oncol Clin North Am       Date:  1992-04       Impact factor: 3.722

4.  'Role of bone marrow stromal cells in the growth of human multiple myeloma.

Authors:  F Caligaris-Cappio; L Bergui; M G Gregoretti; G Gaidano; M Gaboli; M Schena; A Z Zallone; P C Marchisio
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

5.  Human marrow stromal cells: response to interleukin-6 (IL-6) and control of IL-6 expression.

Authors:  J Nemunaitis; D F Andrews; D Y Mochizuki; M B Lilly; J W Singer
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

6.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

Authors:  R Bataille; M Jourdan; X G Zhang; B Klein
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.

Authors:  H Jernberg; M Pettersson; T Kishimoto; K Nilsson
Journal:  Leukemia       Date:  1991-03       Impact factor: 11.528

8.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release.

Authors:  N Kurihara; D Bertolini; T Suda; Y Akiyama; G D Roodman
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

9.  Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.

Authors:  M Nakamura; S Merchav; A Carter; T J Ernst; G D Demetri; Y Furukawa; K Anderson; A S Freedman; J D Griffin
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

10.  Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells.

Authors:  H Kodama; M Nose; S Niida; A Yamasaki
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

View more
  16 in total

1.  Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma.

Authors:  E Cesarman; R G Nador; F Bai; R A Bohenzky; J J Russo; P S Moore; Y Chang; D M Knowles
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 2.  Chemokines in multiple myeloma.

Authors:  Rohit Aggarwal; Irene M Ghobrial; G David Roodman
Journal:  Exp Hematol       Date:  2006-10       Impact factor: 3.084

3.  NF-Kβ Activation in U266 Cells on Mesenchymal Stem Cells.

Authors:  Sara Zahedi; Karim Shamsasenjan; Aliakbar Movassaghpour; Parvin Akbarzadehlaleh
Journal:  Adv Pharm Bull       Date:  2016-09-25

Review 4.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

5.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

6.  A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.

Authors:  Mariateresa Fulciniti; Teru Hideshima; Claudine Vermot-Desroches; Samantha Pozzi; Puru Nanjappa; Zhenxin Shen; Nipun Patel; Ernest S Smith; Wei Wang; Rao Prabhala; Yu-Tzu Tai; Pierfrancesco Tassone; Kenneth C Anderson; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

7.  Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Authors:  Ariel Anguiano; Sascha A Tuchman; Chaitanya Acharya; Kelly Salter; Cristina Gasparetto; Fenghuang Zhan; Madhav Dhodapkar; Joseph Nevins; Bart Barlogie; John D Shaughnessy; Anil Potti
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 8.  Recent advances in understanding the pathogenesis of anemia in multiple myeloma.

Authors:  Franco Silvestris; Marco Tucci; Cosima Quatraro; Franco Dammacco
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

9.  Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.

Authors:  Christine M Ho; Philip L McCarthy; Paul K Wallace; Yali Zhang; Ahmad Fora; Patrick Mellors; Joseph D Tario; Benjamin L S McCarthy; George L Chen; Sarah A Holstein; Sophia R Balderman; Xuefang Cao; Bruno Paiva; Theresa Hahn
Journal:  Blood Adv       Date:  2017-06-20

Review 10.  Cellular mechanisms of multiple myeloma bone disease.

Authors:  Angela Oranger; Claudia Carbone; Maddalena Izzo; Maria Grano
Journal:  Clin Dev Immunol       Date:  2013-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.